What are you searching for?

Sign in
Collaborations & Alliances

Dyadic & Mitsubishi Tanabe Enter Collaboration

The proof of concept partnership will investigate the potential of its C1 technology to produce vital therapeutic proteins

Dyadic International has entered into a funded proof of concept research collaboration to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications with Mitsubishi Tanabe Pharma Corp.

  

“We are very pleased to have the opportunity to collaborate with Mitsubishi Tanabe Pharma Corp. to express two of its important therapeutic compounds using our C1 production platform”, said Mark Emalfarb, Dyadic’s chief executive officer. “This research and development program is aiming to help Mitsubishi Tanabe overcome specific gene expression challenges and to further demonstrate the potential of C1 to become a platform of choice for manufacturing protein-based biologics because of its speed of development and low cost of goods.”


“In this research collaboration, we will be using our proprietary synthetic biology and genome engineering techniques to further modify our C1 host production organism to produce the desired therapeutic proteins”, said Ronen Tchelet, Ph.D., Dyadic’s head of Research.  “We have already proved that our C1 technology is capable of speeding up the development process and producing certain monoclonal antibodies (mAbs) at commercially important levels. We expect this project to generate additional data and to enlarge the diversity of the types of proteins that our C1 platform can potentially produce at higher yields and with lower cost.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics